Tirzepatide treatment statistically and meaningfully reduced HbA1c, and substantially reduced weight, in adults with T2D in the Phase 3 SURPASS studies. PROs in adults treated with tirzepatide 5, 10, or 15 mg in SURPASS-1 to -6 were explored by age, gender, BMI, and weight loss.
Data from all SURPASS-1 to -6 tirzepatide-treated adults were pooled, regardless of dose. Weight-related and health status PRO measures at baseline and endpoint - Ability to Perform Physical Activities of Daily Living (APPADL), Impact of Weight on Self-Perceptions (IW-SP), EQ VAS - were analyzed in participants grouped by age and BMI category at baseline, gender, and weight loss category achieved at endpoint. Analyses used ANCOVA models adjusted for baseline clinical characteristics; ceiling effects were explored in subgroup analyses.
In main and subgroup analyses, lower vs. higher baseline age group was associated with larger improvements in APPADL and EQ VAS scores but smaller improvements in IW-SP score in tirzepatide-treated adults. Lower vs. higher baseline BMI group and greater vs. lesser weight loss group at endpoint were associated with larger improvements across all PRO measures. Improvement in IW-SP score was greater for males vs. females, with no significant difference for other PROs.
Age, BMI, weight loss, and, to a lesser extent, gender all impacted PROs in tirzepatide-treated adults with T2D in the Phase 3 SURPASS studies.
K. Boye: Employee; Eli Lilly and Company. V. Thieu: Employee; Eli Lilly and Company. W. Dong: None. S.E. Williamson: Consultant; Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novo Nordisk, Lundbeck. H. Sapin: None.
